Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...

Full description

Bibliographic Details
Main Authors:	Monika Conchon, Carla Maria Boquimpani de Moura Freitas, Maria Aparecida do Carmo Rego, José Wilson Ramos Braga Junior
Format:	Article
Language:	English
Published:	Elsevier 2011-01-01
Series:	Revista Brasileira de Hematologia e Hemoterapia
Subjects:	Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drug toxicity Drug interactions Gastrointestinal tract Drug resistance, neoplasm Pyrimidines Interferonalpha Piperazines Clinical Trial
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012

Similar Items

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
by: Roberta Bitencourt, et al.
Published: (2011-12-01)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
by: Darlize Hübner Martins, et al.
Published: (2011-01-01)

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
by: Belinda Pinto Simões, et al.
Published: (2011-02-01)

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
by: Samuel Roosevelt Campos dos Reis, et al.
Published: (2013-06-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
by: Vinícius Marcondes Rezende, et al.
Published: (2013-01-01)

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
by: Vinícius Marcondes Rezende, et al.
Published: (2013-01-01)

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012
by: Martín Romero, et al.
Published: (2014-03-01)

Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital
by: Danielle Maria Camelo Cid, et al.
Published: (2013-01-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

Chronic myeloid leukemia: past, present, future
by: Patricia Weinschenker Bollmann, et al.
Published: (2011-06-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts
by: Jae Won Yun, et al.
Published: (2019-03-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Monitoração molecular da Leucemia Mielóide Crônica na era do imatinibe Molecular monitoring of Chronic Myeloid Leukemia in the imatinib era
by: Israel Bendit
Published: (2008-04-01)

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
by: Maria de Lourdes Lopes Ferrari Chauffaille, et al.
Published: (2015-02-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy
by: Stamatović Dragana, et al.
Published: (2012-01-01)

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
by: Begoña San José Ruiz, et al.
Published: (2015-01-01)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019-01-01)

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
by: Maria Juracy Petrola, et al.
Published: (2012-01-01)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
by: Ilana Zalcberg Renault, et al.
Published: (2011-12-01)

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
by: Antonio Almeida, et al.
Published: (2019-08-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Leucemia mieloide crónica, estado del arte Myeloid cronic leukemia, state of the art
by: Luz Aída Rey, et al.
Published: (2009-08-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil
by: Fernando Callera, et al.
Published: (2015-02-01)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017-01-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway
by: Xiaobo Zhang, et al.
Published: (2017-08-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis – Does MTHFR Polymorphism Matter
by: Mohammad Muhsin Chisti, et al.
Published: (2018-07-01)

Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)